Aims/hypothesis Activation of c-jun N-terminal kinase (JNK) has been described in islet isolation and engraftment, making JNK a key target in islet transplantation. The objective of this study was to investigate if JNK inhibition with a cellpermeable TAT peptide inhibitor (L-JNKI) protects functional beta cell mass in human islets and affects AKT and its substrates in islet cells. Methods The effect of L-JNKI (10 μmol/l) on islet count, mitochondrial membrane potential, glucose-stimulated insulin release and phosphorylation of both AKT and its substrates, as well as on reversal of diabetes in immunodeficient diabetic Nu/Nu mice was studied. Results In vitro, L-JNKI reduced the islet loss in culture and protected from cell death caused by acute cytokine exposure. In vivo, treatment of freshly isolated human islets and diabetic Nu/Nu mice recipients of such islets resulted in improved functional beta cell mass. We showed that L-JNKI activates AKT and downregulates glycogen synthase kinase-3 beta (GSK-3B) in human islets exposed to cytokines, while other AKT substrates were unaffected, suggesting that a specific AKT/GSK-3B regulation by L-JNKI may represent one of its mechanisms of cytoprotection. Conclusions/interpretation In conclusion, we have demonstrated that targeting JNK in human pancreatic islets results in improved functional beta cell mass and in the regulation of AKT/GSK3B activity. 
Introduction
In the specific area of islet transplantation, pancreas preservation, islet cell processing and implantation are stress conditions associated with the release of pro-inflammatory cytokines that can impair cell viability and function [1] [2] [3] [4] . Although the pathways of islet loss during isolation and following cytokine-mediated injury may be different, a role for c-jun N-terminal kinase (JNK) activation has been described in both [1] . In addition, JNK plays a major role in early graft failure in experimental models of islet transplantation [5] . JNK is markedly activated in several tissues from diabetic mice [5] . Moreover, JNK inhibition markedly improved rat islet viability [6] and islet engraftment in a syngeneic animal model [6] . Thus, targeting JNK may improve functional beta cell mass via several mechanisms.
In human pancreatic islets, JNK inhibition via an ATPcompetitive agent (SP600125) has been shown to preserve whole-islet mass [4] . In addition, ATP-non-competitive agents, such as small permeable TAT peptide inhibitors of JNK (L-JNKI), have been successfully used by us and others in insulinoma cell line and both murine and porcine islets [7] [8] [9] . We have previously shown that protein transduction domain (PTD) technology can be successfully applied to human islet cell biology. We found that anti-oxidative stress proteins such as haeme oxygenase-1 [10] and anti-apoptotic proteins such as B cell lymphoma associated X protein (Bcl-XL) [11] can be effectively delivered to human islets when coupled to a TAT-derived PTD. Similarly, it has recently been shown that a protease-resistant form of TAT-derived PTD inhibitor of JNK (D-JNKI) can effectively transduce rat and human islets [6] . However, PTDs have a length-and dose-dependent toxicity [12] particularly when used in the D-isoform [6, 8] . Although D-JNKI appears safer in human than in rodent islets [6] , further investigations are warranted prior to their introduction to clinical islet transplantation.
In human pancreatic islets, JNK inhibition has been shown to reduce caspase-3 activity [4] , but the mechanism of islet cell protection by JNK inhibitors remains unclear. Recent data suggest that JNK activation in peripheral tissues affects IRS-1 and/or AKT [13] [14] [15] . A similar regulation of AKT in islet cells would be very important, since AKT has been shown to have a strong influence on pancreatic beta cell growth, function and survival [16] [17] [18] .
In the present study, we investigated whether inhibition of JNK in human islets with a TAT-JNK inhibitory peptide results in improved functional beta cell mass. We demonstrated that L-JNKI protects human islet mass in vitro and partially in vivo. In addition we showed that, under stress generated by exposure to cytokines, L-JNKI activates AKT and downregulates glycogen synthase kinase-3 beta (GSK-3B), while other AKT substrates such as proline-rich AKT substrate (PRAS40) and 70-kDa-S6 kinase (70S6K) were unaffected.
Methods
Islet isolation and assessment of islet recovery and insulin content We obtained 15 human pancreases from deceased, multi-organ donors. Islets were isolated at the Human Cell Processing facility of our Institute using a modification of the automated method [19, 20] . Donor characteristics are shown in Electronic supplementary material (ESM; ESM Table1). Each experiment was performed on five to 11 different pancreases based on the amount of available islets. Research consents were obtained by the Organ Procurement Organization (Life Alliance Organ Recovery Agency, University of Miami, Miami, FL, USA) from the donor family or next of kin. Freshly isolated islets were treated with either TAT peptide alone or with L-JNKI (10 μmol/l; BioSynthesis, Lewisville, TX, USA). After overnight culture, islet counts were obtained and expressed as islet equivalents (IEQ) after diphenylthiocarbazone staining [21, 22] . Data were expressed as percentage of islet loss as compared with 100% placed in culture at day 0. For the assessment of insulin content, cell lysates were collected and insulin content evaluated by ELISA (Mercodia, Winston Salem, NC, USA).
Assessment of beta cell viability and mitochondrial membrane potential For the analysis of viability in the first overnight after isolation, L-JNKI (10 μmol/l) was added within 2 h of isolation and viability assessment performed 12 h after in five different preparations. For the assessment of islet viability in culture, islets were pretreated for 48 h with JNKI or with TAT peptide (10 μmol/l) based on our prior experiments in rodent islets and insulinoma cells [8] . A cocktail of cytokines (IL-1β 50 U/ml, TNF-α 1,000 U/ml and INF-γ 1,000 U/ml) was added 18 h prior to islet dissociation and analysis. Measurement of viable beta cells was performed as described [23] . Briefly, the zinc-binding dye Newport green (NG) allows identification and quantification of islet beta cells on dissociated islets, based on the abundant zinc content in beta cell secretory granules [24] . The membrane exclusion dye 7-aminoactinomycin-D (7AAD; Invitrogen, Carlsbad, CA, USA) was used as marker of cell death. Tetramethylrhodamine ethyl ester (TMRE; Molecular Probes, Eugene, OR, USA) was used to assess mitochondrial membrane potential. Single-cell suspensions from nine different preparations were incubated for 30 min at 37°C with 110 μmol/l NG and 100 ng/ml TMRE, and stained with 7AAD prior to Glucose-stimulated insulin release Dynamic glucosestimulated insulin release (GSIR) was tested on day 2 after isolation in five different preparations as previously described [25] . Briefly, 100 IEQ per condition were loaded on microcolumns connected to an inflow and an outflow port of a customised perifusion system. Media of defined composition were circulated at a rate of 100 μl/min. Fractions of 100 μl were collected every minute. After 1 h pre-incubation in HEPES buffer, sequential circulation of media containing 3 mmol/l glucose (5 min), 11 mmol/l glucose (10 min), 3 mmol/l glucose (15 min), 25 mmol/l KCl (5 min) and 3 mmol/l glucose (5 min) was performed and insulin content determined by ELISA (Mercodia).
Induction of diabetes in Nu/Nu mice All animal manipulations were conducted under protocols approved by the local Islet transplantation in Nu/Nu mice Human islets were treated with 10 μmol/l L-JNKI or with TAT-alone immediately after isolation and on days 1 and 2 of culture, prior to transplantation. Islets (either 2,000, 1,000 or 500 IEQ per mouse) were transplanted in the kidney subcapsular space of diabetic Nu/Nu mice under general anaesthesia [26, 27] . Subsequent experiments, where both islets and recipients were treated with L-JNKI (2 h before transplantation and daily for the following 15 days), were performed with an islet mass of 1,000 IEQ. Normoglycaemia was defined as non-fasting blood glucose values ≤11 mmol/l. Assessment of graft performance during IVGTT was performed in conscious animals at 16, 60, 120 and 127 days after transplantation. Briefly, after overnight fasting, an intravenous glucose bolus (0.5 g/kg) was administered to mice that had achieved normoglycaemia. Glycaemia was measured at baseline and over a 20 min period and AUC (in [mmol× min] dl −1 ) during the first 10 min calculated [20] . Animals with an established graft function (120 days after transplant) received 10 mg/kg L-JNKI intraperitoneally daily for 7 days in order to assess the independent effects of L-JNKI on human islet function in vivo. Preliminary experiments were performed to study peptide transduction efficiency 2 and 24 h after transplantation of islets treated with TAT and/or TAT-FITC intraperitoneal peptide administration (10 mg/kg). Immunofluorescence stainings of graft-bearing kidneys for DAPI (Vector Lab, Burlingame, CA, USA) and insulin (see above) were performed.
Data analysis
Results represent the mean of five to eleven independent experiments from different human pancreases performed in duplicate or triplicate. Results are expressed as scattered dot plots. When one-way ANOVA showed statistical significance, results were compared using t test after Tukey's correction for multiple comparisons (Graph Pad Prism software; San Diego, CA, USA). Statistical significance was set at p<0.05.
Results

L-JNKI preserves islet mass in culture
We examined the loss of islet mass in the first overnight culture after iso-lation, when a strong activation of JNK and cell death pathways occurs [1, 3] . Islets were treated at isolation with 10 μmol/l L-JNKI or TAT alone. L-JNKI protects beta cells from cytokine-induced cell death In order to understand whether L-JNKI may further protect human islet cells that survive the initial overnight culture, and given the fact that JNK activation is transiently low during islet culture at baseline [28] , islets pre-incubated with L-JNKI or with TAT alone were subsequently treated for 18 h with a cocktail of inflammatory cytokines, which are able to activate JNK in selected cultured human islets ( Fig. 2a,b ). We first investigated the relative contribution of different cytokines to JNK phosphorylation in those selected cultures, in which we detected at least a twofold increase in JNK phosphorylation after cytokine exposure and found that IL-1β was mainly responsible for JNK phosphorylation (Fig. 2c) . We found that islet pretreatment with a L-JNKI almost completely prevented cytokine-induced beta cell death (Fig. 3a) . Notably, this effect appears beta-cell-specific, since no protective effect was observed in NG − cells (Fig. 3b) .
Assessment of cellular composition by LSC in the overall population of dissociated islet cells (Table 1) Fig. 2 Effect of cytokines on JNK activity in whole islets. a Human islets were cultured in the presence or absence of a cytokine cocktail (CTK; IL-1β 50 U/ml, TNF-α 1000 U/ml and INF-γ 1000 U/ml) for 18 h. Although there was a high variability from preparation to preparation, cytokine-treatment led to a strong activation of phosphorylated JNK. b Data obtained with Bioplex were confirmed with GST pull-down assay (JNK activity) and with western blot for endogenous c-jun normalized to actin. c To understand the contribution of the different cytokines to JNK activation, human islets with at least a twofold induction of JNK phosphorylation on exposure to the cytokine cocktail were treated either with the cytokine cocktail or with each cytokine alone at the same dose used for the cocktail. IL-1β was the cytokine most responsible for JNK activation in human islets. ***p<0.001 that: (1) cytokines predominantly affect beta cell content and this effect is partially prevented by L-JNKI; (2) the reduction of mitochondrial membrane potential observed with cytokines in NG − cells is accounted for by exocrine tissue; and (3) L-JNKI does not prevent exocrine tissue death. Focusing on islet cells at baseline (i.e. islets untreated with cytokines), we saw that L-JNKI did not affect islet composition or mitochondrial membrane potential either in the beta cell or in the non-beta cell component of dissociated islets cells.
L-JNKI modulates phosphorylation of AKTand GSK-3B AKT has been shown to be an important survival signal for islets [16, 17] ; moreover, in several peripheral tissues activation of JNK resulted in downregulation of AKT phosphorylation [15] . We hypothesised that one of the mechanisms of protection of human islets by L-JNKI may occur through maintenance of an intact autocrine insulin action through AKT, as recently suggested [29] . We found that L-JNKI upregulated AKT phosphorylation (S473) in human islets exposed to inflammatory cytokines (Fig. 4a) . Among several substrates downstream of AKT, we looked at GSK-3B (S9), PRAS40 (T246) and p70S6K (TS421/424). JNK inhibition resulted in downregulation of GSK-3B activity (resulting from increased GSK-3B phosphorylation) (Fig. 4b) , while both PRAS40 and P70S6K were unaffected (Fig. 4c,d) . Interestingly, cytokines stimulated P70S6K irrespectively of whether L-JNKI was present or not. JNK inhibitor affected neither IR (Y1162/1163) nor IRS-1 (S312) (data not shown).
JNKI improves functional beta cell mass in vivo We transplanted human islets treated with L-JNKI or TATalone immediately after isolation and then, in order to correct for the observed preservation of islet mass in each culture condition, recounted to allow an equal amount of IEQ to be transplanted in control and experimental mice. 
Effect of cytokines and L-JNKI on mitochondrial membrane potential. Untreated human islets were compared with islets treated immediately after isolation with L-JNKI (10 μmol/l) or with TATpeptide alone as control (C). A cytokines cocktail (CTK; IL-1β 50 U/ml, TNF-α 1,000 U/ml and INF-γ 1000 U/ml) was added to islets in culture 18 h prior to collection for assessment of mitochondrial membrane potential in beta cells. Values are mean±SD of the percentage of cells positive for insulin (Ins), glucagon (Glu), somatostatin (Som) and PP among endocrine cells. Percentages were obtained as the ratio of total number of cells over purity Cells were dissociated and stained as described in the Methods section. Five different experiments with five independent preparations were performed C Control receiving TAT peptide alone, LJNKI L-TAT-JNKI-treated islets, Cytokines IL-1β 50 U/ml, TNF-α 1,000 U/ml and INF-γ 1000 U/ml treated islets a p<0.05 for cytokines+LJNKI vs cytokines b p<0.01 for cytokines vs C Mice receiving L-JNKI-treated islets received daily intraperitoneal injection of L-JNKI or saline for 16 days and at 2 h prior to transplantation. Preliminary experiments confirmed the transduction of a TAT-FITC peptide 24 h after human islets were treated with TAT-FITC and transplanted under the kidney capsule (Fig. 5) . When we combined L-JNKI treatment of both freshly isolated islets and of transplant recipients (n=5), diabetes reversal was comparable to that of controls (n=4), with a mean reversal time of 11.8±13.1 and 23.5±44.3 days, respectively (NS). One of the four animals in the control group did not achieve normoglycaemia (>100 days). All animals receiving L-JNKI reverted to a non-diabetic state within 30 days of transplant (Fig. 6) . Despite comparable restoration of normoglycaemia in animals in both groups, L-JNKI lead to a much improved glucose tolerance test at day 16 after transplant in the normoglycaemic mice (n=3 per group), in which glycaemic values (at 1 and 4 min) and AUC were improved compared with normoglycaemic controls (Fig. 7a,d ), This effect was partially lost 45 days after interruption of L-JNKI treatment (post-transplant day 60; Fig. 7b,d ) and no longer evident by 120 days after transplant (Fig. 7c,d) . Comparison of AUC values performed within the same group at different time points revealed no differences.
Transplantation of islets treated in vitro with L-JNKI in untreated mice did not result in improved diabetes reversal or glucose tolerance test profiles, when compared with recipients of untreated islets (Table 2) .
We also tested whether a 7 day treatment with L-JNKI had any effect on glucose metabolism in animals bearing functional human islet grafts. In one experimental setting, animals (n=3) underwent IVGTT before initiation and after completion of the L-JNKI therapy. L-JNKI had no effect on the IVGTT profiles in this setting (Fig. 7e) . In additional experiments, two groups of mice (five to six animals per condition) receiving or not the 7-day L-JNKI treatment were tested in parallel. Glycaemic profiles during IVGTT were comparable between groups (111.28±5.27 and 85.6±16.59
[mmol×min] l −1 in control and L-JNHI-treated, respectively; NS). The absence of a specific effect on islet function independent of islet mass was also tested in vitro with dynamic GSIR. We did not observe improved insulin release after stimulation with either 11 mmol/l glucose or 25 mmol/l KCl as assessed by dynamic perfusion studies (Fig. 7f) . Addition of glucagon-like peptide-1 (GLP-1) at 30 min before and/or during perifusion did not modify the perifusion profiles (data not shown). 
AKT (S473) P70S6K (T246) GSK3 (S9) Fig. 4 Effect of cytokines and L-JNKI on AKT signalling pathway. We studied 25μg of cell lysates for each condition. 
Discussion
The inflammatory response activated in the pancreas at the time of isolation and implantation is secondary to multiple events, such as donor brain death, pancreas procurement, organ preservation, islet isolation and early stages of transplantation [30] [31] [32] . Interestingly, recent data suggest that JNK may represent a key target factor of such an inflammatory response [1, 33, 34] , since activation of JNK during islet isolation and engraftment is detrimental to islet cell survival [4, 5, 9, 24] . Both ATP-competitive and noncompetitive JNK inhibitors have shown biological activity in pancreatic islets [4, 9] , although we and others have shown that some cell-permeable peptides may be toxic to islet cells [5, 8, 12] . We first compared the activity of L-JNKI and of an irrelevant TAT-peptide on the protection of islet mass, consistent with results reported in porcine and murine islets [8, 9] . TAT peptide alone was used as control, because our previous observation did not show any difference in toxicity between TAT alone and the L-isoform of TAT-JNKI in porcine islets [8] . L-JNKI showed the expected protective effects on islet mass (Fig. 1a) . Interestingly, this was not associated with an improvement of beta cell viability (Fig. 1b) or with higher insulin content. This suggests that the protective effect of JNK in the first overnight culture might be very different from the one observed after cytokine exposure in culture and might involve factors responsible for the protection of islet disruption. It is conceivable that the observed effects of L-JNKI could be markedly improved by use of the protease-resistant D-JNKI, which has recently been shown to be safe and effective in human islets even when used at higher concentrations [6] .
While activation of JNK is high in the early phases during and immediately after isolation, it becomes almost undetectable in culture [28] . Thus, activation of JNK in vitro would occur only in the presence of stress stimuli, among which Mice were killed 24 h after treatment we focused our attention on inflammatory cytokines (IL-1β, TNFα and INFγ), which have been shown to be relevant to islet viability and function [35] [36] [37] and are markedly activated in early islet transplantation even when islets are transplanted under the kidney capsule [38] . We first confirmed that JNK is markedly phosphorylated in cultured human islets by a cocktail of inflammatory cytokines and that increased phosphorylation is associated with increased JNK activity (Fig. 2a,b) . It is important to note that inflammatory cytokines can upregulate other mediators of cell death such as nuclear factor kappa-B and p-38 [28, 39] , but we deliberately focused our attention on JNK. Interestingly, there was a high degree of variability in the susceptibility of different islet preparations to cytokines. However, analysis of donor-related characteristics (see ESM Table1) failed to identify a factor responsible for such variability. Among the islet preparations with at least a twofold induction of JNK Nu/Nu mice recipients of untreated or L-JNKI-treated islets (with three different graft sizes of 500, 1,000 or 2,000 IEQ per mouse) were followed after transplantation and screened for time to reversal of diabetes. Time to diabetes reversal was similar in mice recipients of TAT alone treated islets (Control) or of L-JNKI treated islets (L-JNKI) Number of mice in the same group with same time to reversal of diabetes: a 3 b 1 phosphorylation by cytokines, the cytokine IL-1β was mainly responsible for such activation (Fig. 2c) . In order to test the hypothesis that L-JNKI specifically protects beta cells, we evaluated the mitochondrial membrane potential of both beta cell and non beta cell subsets of dissociated human islets, since dissipation of the mitochondrial membrane potential is a feature of apoptotic and necrotic beta cell damage [23] . We found that cytokines predominantly affect beta cells and that pretreatment with L-JNKI prevents this phenomenon (Fig. 3a) , consistent with the percentage of beta cells observed by LSC in cytokinetreated islets exposed to L-JNKI ( Table 1 ). The observed modulation of the mitochondrial transmembrane potential by cytokine exposure could be the result of excessive nitric oxide production resulting in inhibition of mitochondrial complex 4 [1, 40] and potentiation of JNK activity [41] . When we selectively analysed the NG − subpopulation of cells, we found that cytokines markedly reduced the mitochondrial membrane potential in those cells as well, but that L-JNKI had no effect (Fig. 3b) . Thus, quantitative analysis of cellular composition by LSC was used to determine whether the population of NG − cells affected by cytokines were non-beta islet cells or exocrine cells. We found that cytokine treatment had no significant effects on glucagon, somatostatin or PP positive cells ( [42] . Since the integrity of the insulin signalling cascade in beta cells is responsible for preservation of beta cell mass and for insulin secretion [43] , and since JNK inhibition affects IRS-1/AKT in peripheral tissues [13] [14] [15] , we tested the effect of L-JNKI in human islet insulin pathway with our main focus on AKT and its substrates. Among those substrates, GSK-3B and p70S6K participate in the regeneration of beta cell mass via increased mitogenesis [44, 45] , while PRAS40 is also activated by insulin in peripheral tissues and is implicated in protection of neurons against ischaemic injury [46, 47] . We found that JNK inhibition in human islets treated with either L-JNKI or SP600125 specifically stimulated the phosphorylation of AKT and GSK-3B (Fig. 4a,b) . However, this effect was observed only when islets were stimulated with cytokines, although cytokines alone did not affect either AKT or GSK-3. The activation of both AKT and GSK3 by cytokines is interesting, since it has been shown in haemopoietic cells that cytokine-induced phosphorylation of GSK-3 is AKTindependent [48] . Overall, these findings suggest that cytokines normally stimulate both the AKT/GSK3 and JNK pathways, the latter usually being predominant and preventing a significant increase in AKT phosphorylation. It is possible that high doses of insulin and IGF-1 in the islet media may affect islet viability by overcoming the activation of JNK, as suggested elsewhere [28] . L-JNKI did not affect PRAS40 either at baseline or after cytokine exposure. This was surprising, since the AKT-mediated protection against apoptosis of neurons exposed to an ischaemic event has been shown to be mediated by PRAS40 [47] . Similarly, L-JNKI did not affect p70S6K, although cytokines activated p70S6K similarly to results reported in adipocytes exposed to IL-1β [49] . The lack of regulation of IRS (S312) phosphorylation by L-JNKI was also unexpected. However, multiple other serine sites could represent the target of L-JNKI, but were not assessed in this study.
We then studied whether the beneficial effect of L-JNKI in islets may persist in vivo. We first verified that a TAT-FITC cell-permeable peptide can transduce human islets (Fig. 5) . To assess the effect of L-JNKI in vivo, we evaluated the proportion of animals with diabetes reversal and performed IVGTT in mice recipients of islets exposed to L-JNKI. We found that L-JNKI was able to improve IVGTT profiles in vivo only when administered to cultured islets and to recipient mice in the peri-transplantation period (Fig. 7a,d ), but not when islets alone were treated with L-JNKI ( Table 2) or when treatment was given to animals bearing established human islet grafts (Fig. 7e) . These results suggest that L-JNKI did not exert an independent activity on established graft function, although early islet performance was improved by the JNK inhibitor's ability to reduce local inflammation at the graft site. To further analyse an independent ability of L-JNKI to affect islet function, we tested the ability of L-JNKI to improve GSIR in whole islets in vitro (Fig. 7f) . We found that L-JNKI administered prior to stimulation with 11 mmol/l glucose did not lead to an increase in insulin secretion. When the same experiments were performed in the presence of GLP-1, no significant increase in insulin secretion was observed (data not shown). This is consistent with findings in betaTC3 cells treated with an L-JNKI [7] , although an ATP-competitive JNKI was shown to improve insulin secretion by human islets in the presence of 3-isobutyl-1-methylxanthine (IBMX), a cAMP phosphodiesterase inhibitor [4] . Thus, the better glucose tolerance test profiles observed in diabetic mice treated with L-JNKI and receiving islets treated with L-JNKI probably reflects an L-JNKI-induced improvement of islet early engraftment and performance. Since our in vitro studies pointed to the protective effect of JNK inhibition on islet survival in the presence of a proinflammatory environment, the beneficial effect of L-JNKI treatment in vivo appears to be consistent with local cytoprotection of the graft early after transplantation. However, the systemic anti-inflammatory properties of JNK inhibition may have contributed to the observed protection [50] . We ruled out the possibility that the improvement of the AUC in Fig. 7d could be explained by a systemic improvement in insulin sensitivity [14] , since administration of a JNK inhibitor in mice with an established graft did not show any benefit. The relative contribution of the local versus systemic effects of JNK inhibition to the improved graft performance, as well as the loss of benefit of L-JNKI treatment upon drug discontinuation, warrant further investigation.
In conclusion, we have shown that L-JNKI is functional in human islets and protects functional beta cell mass both in vitro and in vivo in the early post transplant period. The protective effect of L-JNKI in human islets following acute cytokine exposure is associated and probably mediated by phosphorylation of AKT and GSK-3B. Thus, the introduction of JNK inhibitors in clinical islet isolation and transplantation may allow for a better preservation of islet mass and for improvement of islet engraftment.
